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Anti-tumor activity of stem cell-derived extracellular vesicles
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Extracellular vesicles (EVs) have gathered a 
substantial amount of interest over the past years, as an 
intercellular communication system for biologically 
active molecules, such as mRNAs, miRNAs, lipids and 
proteins [1]. The ability of stem cell-EVs to reprogram 
recipient cells has been demonstrated in different tissues 
and pathologies. In oncology, several groups approached 
the possible use of stem cell-derived EVs to inhibit tumor 
growth and progression, with conflicting results.
Recently, Lopatina et al. demonstrated that EVs 
derived from a resident population of human liver stem 
cells with mesenchymal characteristics exert anti-
angiogenic effect on tumor-derived endothelial cells (TEC) 
from renal carcinomas. This effect was confirmed in vivo, 
when systemically injected EVs affected human TEC-
derived vessels connected with the mouse vasculature [2]. 
Of relevance, liver stem cell-EVs showed a selective effect 
on TECs, as they were ineffective on normal endothelial 
cells. This could be explained by the activity of EVs on 
altered gene expression profile of tumor, and not normal, 
endothelium. Indeed, it is well known that TECs display 
an altered phenotype, and that they might derive from 
modified endothelial cells recruited from tumor adjacent 
vessels as well as from an intra-tumor vasculogenesis [3]. 
Concerning this possibility, renal TECs might originate 
from the endothelial differentiation of cancer stem cells 
(CSCs), a well-recognized sub-population of tumor cells 
able to sustain the initiation, the maintenance and the 
recurrence of solid tumors [3]. Of interest, it has been 
recently demonstrated that liver stem cell-EVs also induce 
apoptosis of renal CSCs, alone or in combination with 
drugs commonly used in clinical practice, highlighting a 
double, although different, effect of liver stem cell-EVs on 
both tumor endothelial and cancer stem cells [2, 4]. 
Tumor angiogenesis might be differently modulated 
by stem cell-derived EVs of different origin. For instance, 
mesenchymal stem cell (MSC)-EVs were shown to 
promote tumor vascularisation in gastric and colon cancer 
models [5]. At variance, Lee et al. described the in vitro 
and in vivo inhibition of angiogenesis driven by MSC-
EVs through vascular endothelial growth factor down-
regulation in breast cancer [6]. In the paper of Lopatina 
et al., MSC-EVs, at variance of liver stem cell-EVs, 
failed to inhibit tumor angiogenesis, [2] and similar lack 
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Figure 1: Anti-tumor effect of stem cell-derived EVs. Stem cell-derived EVs could act in different steps of tumor progression, by 
targeting tumor endothelial cells, cancer stem cells and differentiated tumor cells. The direct transfer of specific anti-angiogenic miRNAs, 
(such as miR-181b, miR-320c, miR-874, miR-16 and miR-146), by stem cell-derived EVs to endothelial cells may result in reduced tumor 
vascularization. Due to the aberrant vascularization of tumors, and to the presence of fenestrations in the endothelium, EVs could efficiently 
reach both tumor epithelial cells and cancer stem cells in their perivascular niche, where the transfer of other anti-tumor miRNAs, such as 
miR-451, miR-31, and miR-223, may affect specific pathways responsible for tumor growth and survival.
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of activity was also reported in a recent study on murine 
lymphomas [7]. This variable activity of stem cell-EVs 
may possibly depend on the type of stem cell originating 
EVs as well as on their target. In this context, EVs from 
MSCs rather appear to display a general pro-angiogenic 
activity, of value for tissue regeneration. At variance, 
cardiac stem cell-derived EVs were able to reduce tumor 
vascularization in parallel with tumor proliferation, in 
vitro and in vivo [7]. Other reported sources of EVs with 
anti-tumor activity were human embryonic stem cell [8] 
and placental stem cells [9].
The described effect of stem cell-EVs on tumor 
cells has been mainly ascribed to the transfer of specific 
miRNAs able to reprogram their gene expression profile 
(Figure 1). In particular, among the anti-angiogenic 
miRNAs identified in liver stem cell-EVs, miR-181b, 
miR-320c and miR-874 were described as responsible 
of the down-regulation of tumor angiogenic factors such 
as FGF1 and PLAU [2]. In addition, miR-16, enriched 
in MSC-EVs, was also reported to contribute to vascular 
endothelial growth factor down-regulation in breast cancer 
cells [6] and miR-146, highly enriched in cardiac stem 
cell-EVs, was implicated in their anti-angiogenic and 
anti-tumor effects [7]. Moreover, liver stem cell-EVs were 
shown to transfer other anti-tumor miRNAs, such as miR-
451, miR-31, and miR-223 to hepatoma cells, inducing 
a down-regulation of their targets (MDR1, RAB14, MIF 
and E2F-2) [10]. As result, intracellular pathways relevant 
for tumor growth and survival, such as Akt/mTOR/PTEN, 
were down-regulated by EV treatment [4]. In addition, a 
synergistic activity of stem cell-EVs was observed with 
tyrosine kinase inhibitors, enhancing the blockade of 
tumor intracellular pathways in CSCs [4]. 
Altogether, these data provide a rationale for the 
use of stem cell-derived EVs, from a number of different 
stem cell sources, for the treatment of solid tumors. Of 
interest, stem cell-derived EVs appear to act on multiple 
targets such as tumor endothelial cells, tumor stem cells 
as well as on differentiated cells (Figure 1). Indeed, stem 
cell-EVs may display a unique anti-tumor effect thanks to 
a variety of molecular species within their cargo and to an 
orchestrated activity on multiple pathways.
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